Financial Data and Key Metrics Changes - Revenue for Q2 2022 increased by 76% year-over-year to $109.5 million, up from $62.2 million in Q2 2021 [6][20] - Adjusted EBITDA for Q2 2022 grew to $12.3 million, compared to $3.4 million in the prior year [25] - Net income for Q2 2022 was $11.8 million, a significant improvement from $100,000 in Q2 2021 [23][24] - Total gross margin percentage increased to 35.9% in Q2 2022 from 34% in the same period of 2021 [26] Business Line Data and Key Metrics Changes - Mobile health revenue for Q2 2022 was $87.3 million, up 163% from $33.2 million in Q2 2021 [21] - Excluding mass COVID testing, mobile health revenue was $59.3 million, an increase of 156% year-over-year [21] - Medical transportation revenues decreased to $22.2 million from $28.9 million in Q2 2021, with recurring transportation revenues increasing by 8% to $20.2 million [21][22] Market Data and Key Metrics Changes - Revenue generated from the UK market increased by 45% to $3.2 million, representing approximately 3% of total revenue [23] - Mass COVID testing revenues for the quarter were approximately $28 million, expected to decline significantly in Q3 [7][31] Company Strategy and Development Direction - The company is focusing on expanding its mobile health services and pursuing M&A opportunities to enhance profitability and market reach [9][40] - The transition from COVID-related services to primary care and other non-COVID services is expected to be seamless, with minimal impact on revenue generation [8][54] - The company aims to maintain a strong balance sheet and cash flow to support growth initiatives [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about strong operational execution and increased revenue guidance for 2022, now projected between $425 million and $435 million [6][33] - The company anticipates continued demand for mobile health and transportation services, with a focus on municipal contracts as a stable revenue source [11][54] - Management acknowledged inflationary pressures on labor and fuel costs but remains committed to improving gross margins [30][44] Other Important Information - The company has significantly enhanced its RFP capabilities, allowing for increased bidding on larger contracts [11] - DocGo's NPS score for mobile health services was an impressive 77, indicating strong customer satisfaction [14] - The company announced a share repurchase program of up to $40 million, having repurchased 70,000 shares at an average cost of $7.10 during the quarter [29] Q&A Session Summary Question: Can you provide transport volumes and pricing for the quarter? - Management did not disclose specific transport volumes but indicated an increase in trip volume and price per call, projecting a 30% growth in transportation revenue [35][36] Question: What is the outlook for M&A opportunities? - The focus is on mobile health services, with expectations of more opportunities arising in the near future [39][40] Question: How does the guidance reflect organic growth versus M&A? - The increase in guidance is primarily based on organic growth, with some small tuck-in acquisitions for licensing capabilities [42][43] Question: What are the expectations for gross margins in the second half of the year? - Management expects to maintain or improve gross margins, despite inflationary pressures [44][56] Question: Can you provide insights on new contracts and the pipeline? - Management noted strong contract signing activity and a robust pipeline, particularly in municipal contracts [49][54]

[PART I - FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements, including balance sheets, statements of operations, changes in stockholders' equity, and cash flows, with accompanying notes [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheets (June 30, 2022 vs. December 31, 2021) | Metric | June 30, 2022 | December 31, 2021 | | :--------------------------- | :---------------- | :---------------- | | Total Assets | $331,855,388 | $309,602,652 | | Total Liabilities | $77,461,692 | $82,545,628 | | Total Stockholders' Equity | $254,393,696 | $227,057,024 | [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20%28Loss%29) Revenue, Net | Period | 3 Months Ended June 30, 2022 | 3 Months Ended June 30, 2021 | 6 Months Ended June 30, 2022 | 6 Months Ended June 30, 2021 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | **Amount** | $109,519,304 | $62,185,997 | $227,410,856 | $111,555,391 | | **YoY Change (3 Months)** | **+76.1%** | | | | | **YoY Change (6 Months)** | | | **+103.9%** | | Net Income (Loss) Attributable to Stockholders of DocGo Inc. and Subsidiaries | Period | 3 Months Ended June 30, 2022 | 3 Months Ended June 30, 2021 | 6 Months Ended June 30, 2022 | 6 Months Ended June 30, 2021 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | **Amount** | $12,735,653 | $(1,646,216) | $23,365,347 | $(3,324,580) | Net Income (Loss) Per Share Attributable to DocGo Inc. and Subsidiaries | Metric | 3 Months Ended June 30, 2022 | 3 Months Ended June 30, 2021 | 6 Months Ended June 30, 2022 | 6 Months Ended June 30, 2021 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | **Basic** | $0.13 | $(18.19) | $0.23 | $(36.73) | | **Diluted** | $0.11 | $(18.19) | $0.20 | $(36.73) | [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) - Total Stockholders' Equity increased from **$227,057,024** as of December 31, 2021, to **$254,393,696** as of June 30, 2022[18](index=18&type=chunk) - Common Stock issued and outstanding increased to **100,685,290** shares as of June 30, 2022, from **100,133,953** shares as of December 31, 2021[18](index=18&type=chunk) - Additional paid-in capital increased by **$4,140,251** from December 31, 2021, to June 30, 2022, primarily due to stock option exercises and stock-based compensation[18](index=18&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net Cash Flow by Activity (Six Months Ended June 30) | Activity | 2022 | 2021 | | :-------------------------------- | :---------------- | :---------------- | | Net cash provided by operating activities | $30,186,977 | $(1,145,393) | | Net cash used in investing activities | $(1,958,085) | $(3,599,334) | | Net cash provided by financing activities | $1,122,290 | $7,048,733 | | Net increase in cash and restricted cash | $29,355,753 | $2,406,659 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures for the unaudited condensed consolidated financial statements, covering business operations, accounting policies, assets, liabilities, equity, revenue recognition, and other financial instruments [1. Description of Organization and Business Operations](index=10&type=section&id=1.%20Description%20of%20Organization%20and%20Business%20Operations) - DocGo Inc. completed a business combination with Ambulnz, Inc. on **November 5, 2021**, making Ambulnz a wholly-owned subsidiary[31](index=31&type=chunk)[32](index=32&type=chunk) - The business combination generated **$158.0 million** in net proceeds, including **$43.4 million** from Motion's trust account and **$114.6 million** from PIPE Financing[33](index=33&type=chunk) - DocGo operates as a healthcare transportation and mobile health services company, utilizing proprietary dispatch and communication technology in the U.S. and U.K[34](index=34&type=chunk) [2. Summary of Significant Accounting Policies](index=11&type=section&id=2.%20Summary%20of%20Significant%20Accounting%20Policies) - The merger between Motion and Ambulnz was accounted for as a reverse recapitalization, with Ambulnz, Inc. treated as the accounting acquirer for financial reporting purposes[42](index=42&type=chunk) - The Company consolidates MD1 Medical Care P.C. as a variable interest entity (VIE) due to its controlling financial interest[44](index=44&type=chunk) - As of June 30, 2022, two major customers accounted for approximately **30%** and **17%** of sales, and **15%** and **12%** of net accounts receivable, respectively[52](index=52&type=chunk) Revenue by Geographical Markets (Six Months Ended June 30) | Market | 2022 | 2021 | | :----- | :--- | :--- | | U.S. | $221,368,244 | $107,308,709 | | U.K. | $6,042,612 | $4,246,682 | | **Total** | **$227,410,856** | **$111,555,391** | Revenue by Major Segments/Service Lines (Six Months Ended June 30) | Segment | 2022 | 2021 | | :--------------------------- | :---------------- | :---------------- | | Transportation Services | $49,987,743 | $47,740,979 | | Mobile Health | $177,423,113 | $63,814,412 | | **Total** | **$227,410,856** | **$111,555,391** | [3. Property and Equipment, net](index=20&type=section&id=3.%20Property%20and%20Equipment%2C%20net) Property and Equipment, Net (June 30, 2022 vs. December 31, 2021) | Category | June 30, 2022 | December 31, 2021 | | :--------------------------- | :---------------- | :---------------- | | Office equipment and furniture | $2,292,194 | $1,977,808 | | Buildings | $527,284 | $527,284 | | Land | $37,800 | $37,800 | | Transportation equipment | $14,027,121 | $13,772,251 | | Medical equipment | $4,285,584 | $3,949,566 | | Leasehold improvements | $603,073 | $616,446 | | **Total Gross** | **$21,773,056** | **$20,881,155** | | Less: Accumulated depreciation | $(9,543,059) | $(8,147,266) | | **Property and equipment, net** | **$12,229,997** | **$12,733,889** | - Depreciation expense for the six months ended June 30, 2022, was **$1,441,438**, up from **$1,099,192** in

Financial Data and Key Metrics Changes - Total revenue for Q1 2022 was $118 million, a growth of 137% compared to Q1 2021 [6][25] - Adjusted EBITDA for Q1 2022 was $13.9 million, significantly improved from $0.4 million in Q1 2021, with an adjusted EBITDA margin of 11.8% [8][25] - Net income for Q1 2022 was $9.4 million, a substantial improvement from a net loss of $2 million in Q1 2021 [9][25] - Cash and cash equivalents as of March 31, 2022, totaled $188.4 million, up from $135.5 million at the end of 2021 [28] Business Line Data and Key Metrics Changes - Mobile Health division generated revenue of $90.1 million in Q1 2022, a 193% increase from $30.7 million in Q1 2021 [7][25] - Transportation revenue was $27.8 million, a 46% increase from $19 million in Q1 2021 [8][25] - Excluding COVID testing revenue, total Q1 revenues increased approximately 2.7 times year-over-year, from about $29 million in Q1 2021 to approximately $80 million in Q1 2022 [25] Market Data and Key Metrics Changes - The UK market revenue grew by 40% to $2.8 million during Q1 2022, representing about 2% of total revenue [25] - The company provided services in 29 states and the UK, with significant growth opportunities in both existing and new markets [10][20] Company Strategy and Development Direction - The company aims to transition from COVID-related services to longer-term non-COVID work, focusing on building lasting customer relationships [9][19] - Plans to expand direct-to-consumer offerings and enhance technology integration with existing healthcare systems [15][64] - The company is pursuing international expansion, particularly in the UK, while also targeting the untapped U.S. market [20][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand for mobile health and transportation services, maintaining revenue guidance of $400 million to $420 million for 2022 [31][54] - The transition from COVID testing to new mobile health contracts is expected to be seamless, with a focus on timing and resource allocation [41][60] - Management highlighted the significant market opportunity for home-based care, projecting a shift of up to $265 billion in medical care to home settings by 2025 [23] Other Important Information - The company unveiled the first zero-emission all-electric ambulance in the U.S. and aims to convert to an all-electric fleet by 2032 [21] - The company has expanded its workforce, with over 4,000 full-time personnel, primarily clinical providers, and anticipates reaching around 5,000 by year-end [44] Q&A Session Summary Question: What is the COVID testing revenue for 2021? - The estimated COVID testing revenue for 2021 was $110 million, with an anticipated $55 million for 2022 in the first half [36][37] Question: How is the transition from COVID contracts to long-term work progressing? - The transition is primarily about timing, ensuring personnel are ready for new contracts as COVID work winds down [41][42] Question: What is the final provider headcount at the quarter end? - The final provider headcount was over 4,000, with expectations to reach around 5,000 by the end of the year [44] Question: How does the revenue transition from COVID testing to new services look? - The revenue model remains consistent, with minimal variation as practitioners transition from COVID testing to other clinical services [45][46] Question: What are the gross margin targets for mobile health and transportation? - Long-term gross margin targets are 50% to 53% for mobile health and 40% to 42% for transportation [69]

[PART I - FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents the unaudited condensed consolidated financial statements for the three months ended March 31, 2022, and 2021, including balance sheets, statements of operations, changes in stockholders' equity, and cash flows, along with detailed notes [Condensed Consolidated Financial Statements](index=5&type=section&id=Condensed%20Consolidated%20Financial%20Statements) For Q1 2022, DocGo reported significant year-over-year revenue growth, primarily driven by its Mobile Health segment, achieving a net income of **$9.4 million** from a prior-year net loss, with increased total assets and cash reserves Condensed Consolidated Statement of Operations (Q1 2022 vs Q1 2021) | Metric | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | **Revenue, net** | $117,891,552 | $49,688,856 | | **Income (loss) from operations** | $10,094,565 | ($1,873,958) | | **Net income (loss)** | $9,372,437 | ($1,998,996) | | **Net income (loss) attributable to stockholders** | $10,629,694 | ($1,678,364) | | **Net income (loss) per share - Basic** | $0.11 | ($0.03) | | **Net income (loss) per share - Diluted** | $0.09 | ($0.03) | Condensed Consolidated Balance Sheet Highlights | Metric | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $188,353,909 | $175,537,221 | | **Total current assets** | $268,170,785 | $256,032,491 | | **Total assets** | $325,196,304 | $309,602,652 | | **Total current liabilities** | $60,992,489 | $57,875,921 | | **Total liabilities** | $84,931,995 | $82,545,628 | | **Total stockholders' equity** | $240,264,309 | $227,057,024 | Condensed Consolidated Statement of Cash Flows (Q1 2022 vs Q1 2021) | Metric | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | **Net cash provided by (used in) operating activities** | $18,264,682 | ($1,384,175) | | **Net cash used in investing activities** | ($1,137,040) | ($1,276,054) | | **Net cash provided by (used in) financing activities** | $2,496,798 | ($550,591) | | **Net increase (decrease) in cash and restricted cash** | $19,618,577 | ($3,202,822) | [Notes to Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's business operations, significant accounting policies, and specifics on financial statement line items, including reverse recapitalization accounting, revenue disaggregation, customer concentration, stock-based compensation, and COVID-19 impact - The company operates as a healthcare transportation and mobile health services provider in the US and UK, becoming a public company (DocGo Inc.) on November 5, 2021, after a merger with Motion Acquisition Corp, accounted for as a reverse recapitalization with Ambulnz, Inc. as the accounting acquirer[28](index=28&type=chunk)[31](index=31&type=chunk)[38](index=38&type=chunk) Revenue by Segment and Geography (Q1 2022 vs Q1 2021) | Category | Service Line | Q1 2022 Revenue | Q1 2021 Revenue | | :--- | :--- | :--- | :--- | | **Segment** | Transportation Services | $27,812,510 | $19,124,020 | | | Mobile Health | $90,079,042 | $30,564,836 | | **Geography** | United States | $115,053,431 | $47,681,374 | | | United Kingdom | $2,838,121 | $2,007,482 | | **Total** | | **$117,891,552** | **$49,688,856** | - The company has significant customer concentration, with two customers accounting for **34%** and **19%** of sales, respectively, for the quarter ended March 31, 2022[48](index=48&type=chunk) - The COVID-19 pandemic had a mixed impact, reducing non-emergency medical transport volumes but significantly boosting revenue through the company's Rapid Reliable Testing (RRT) subsidiary, part of the Mobile Health segment[181](index=181&type=chunk)[182](index=182&type=chunk) - As of March 31, 2022, the company had **$22.9 million** in total unrecognized compensation related to unvested stock option awards, expected to be recognized over a weighted-average period of **3.58 years**[149](index=149&type=chunk) - The company recorded a liability of **$1,000,000** for an agreed settlement related to various class-based claims under Federal and California State law, which is subject to court approval[178](index=178&type=chunk) [Management's Discussion and Analysis (MD&A)](index=35&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's Q1 2022 performance, highlighting a **137%** increase in total revenue to **$117.9 million**, driven by a **194%** surge in Mobile Health services, achieving a net income of **$9.4 million** from a prior-year loss [Results of Operations](index=39&type=section&id=Results%20of%20Operations) In Q1 2022, total revenues grew **137%** to **$117.9 million**, with Mobile Health revenue increasing **194%** to **$90.1 million** and Transportation Services revenue growing **46%** to **$27.8 million**, leading to improved gross margin and an operating income of **$10.1 million** Consolidated Results of Operations (in Millions) | Metric | Q1 2022 | Q1 2021 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | **Revenues, net** | $117.9 | $49.7 | $68.2 | 137% | | **Cost of revenue** | $78.0 | $35.9 | $42.1 | 117% | | **Income/(loss) from operations** | $10.1 | ($1.9) | $12.0 | N/A | | **Net income (loss)** | $9.4 | ($2.0) | $11.4 | N/A | - Mobile Health revenue surged by **194%** to **$90.1 million**, primarily due to the expansion of COVID-19 related testing and other healthcare services[224](index=224&type=chunk) - Transportation Services revenue increased by **46%** to **$27.8 million**, driven by a **5%** rise in trip volumes and a significant increase in the average price per trip from **$283** to **$353**[223](index=223&type=chunk) - Cost of revenue as a percentage of revenue decreased to **66.2%** from **72.2%** in Q1 2021, indicating improved gross margin despite increased absolute costs for labor, supplies, and fuel[225](index=225&type=chunk) [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity position is strong, with cash of **$188.4 million** and working capital of **$207.2 million** as of March 31, 2022, primarily due to November 2021 merger proceeds and **$18.2 million** in cash generated from operations - The company received net proceeds of approximately **$158.1 million** from its merger in November 2021, significantly bolstering its liquidity[240](index=240&type=chunk) Working Capital (in Millions) | Metric | March 31, 2022 | March 31, 2021 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | **Current Assets** | $268.2 | $62.7 | $205.5 | 328% | | **Current Liabilities** | $61.0 | $31.0 | $30.0 | 97% | | **Total working capital** | $207.2 | $31.7 | $175.5 | 554% | - Net cash provided by operating activities was **$18.2 million** for Q1 2022, a significant improvement from the **$1.4 million** used in Q1 2021, driven by net income and favorable working capital changes[246](index=246&type=chunk) [Critical Accounting Policies](index=45&type=section&id=Critical%20Accounting%20Policies) This section outlines the company's most critical accounting policies, which involve significant judgments and estimates, including the basis of presentation (reverse recapitalization), consolidation of a Variable Interest Entity (VIE), business combinations, goodwill impairment testing, revenue recognition, and income taxes - The merger with Motion Acquisition Corp. was accounted for as a reverse recapitalization, with Ambulnz, Inc. treated as the accounting acquirer[256](index=256&type=chunk) - The company consolidates MD1 Medical Care P.C., a Variable Interest Entity (VIE), because it has the power to direct its activities and absorbs its losses[258](index=258&type=chunk) - Goodwill and indefinite-lived intangible assets are not amortized but are tested for impairment annually on December 31, or more frequently if events indicate potential impairment[264](index=264&type=chunk)[266](index=266&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=47&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company is classified as a smaller reporting company and is therefore not required to provide the disclosures typically found under this item - As a smaller reporting company, DocGo is exempt from the requirement to provide quantitative and qualitative disclosures about market risk[273](index=273&type=chunk) [Controls and Procedures](index=47&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of March 31, 2022, with no material changes to internal control over financial reporting identified during the quarter - Management concluded that the company's disclosure controls and procedures are effective in ensuring timely and accurate reporting[274](index=274&type=chunk) - There were no changes during the quarter ended March 31, 2022, that materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[275](index=275&type=chunk) [PART II - OTHER INFORMATION](index=48&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Legal Proceedings & Risk Factors](index=48&type=section&id=Item%201.%20Legal%20Proceedings%20%26%20Item%201A.%20Risk%20Factors) The company is involved in legal proceedings arising in the ordinary course of business, and while most risk factors remain unchanged from the 2021 Form 10-K, a new risk related to inflation has been highlighted due to increasing costs compressing gross margins - The company is subject to legal proceedings and government information requests that arise in the ordinary course of business[277](index=277&type=chunk)[278](index=278&type=chunk) - A new inflation rate risk has been identified, noting that the high inflation rate in Q1 2022 (reaching **8.5%** in March) has increased expenses for wages, fuel, and medical supplies, compressing gross profit margins[280](index=280&type=chunk) [Other Disclosures (Items 2, 3, 4, 5, 6)](index=48&type=section&id=Other%20Disclosures%20%28Items%202%2C%203%2C%204%2C%205%2C%206%29) This section confirms there were no unregistered sales of equity securities, no defaults upon senior securities, and no other material information to report during the period, with a list of exhibits filed with the 10-Q provided - The company reports no unregistered sales of equity securities, defaults on senior securities, mine safety disclosures, or other information for the quarter[280](index=280&type=chunk)[281](index=281&type=chunk)[282](index=282&type=chunk)[283](index=283&type=chunk)

Financial Data and Key Metrics Changes - Full year 2021 total company revenue reached $318.7 million, a growth of over 239% compared to $94 million in 2020 [5][29] - Adjusted full year 2021 EBITDA was $25.1 million, a significant improvement from an adjusted EBITDA loss of $8.1 million in 2020 [6][31] - Net income for the full year was $19.2 million, compared to a net loss of $14.8 million in 2020 [31][32] - Q4 2021 total revenue was over $121 million, representing a growth of 289% from $31 million in Q4 2020 [27][29] - Q4 adjusted EBITDA grew to $17.3 million, compared to an EBITDA loss of $2.9 million in the prior year [28][31] Business Line Data and Key Metrics Changes - Mobile Health revenue for fiscal 2021 was $234.4 million, up 659% from $31 million in the prior year [29] - Medical transportation revenue amounted to $84.3 million, a 33% increase from $63.1 million in fiscal 2020 [29] - Q4 Mobile Health revenue was $102.6 million, compared to $15.8 million in Q4 2020, reflecting a growth of approximately 6.5 times [27][28] - Medical transport revenue in Q4 was $18.7 million, up 21% from $15.4 million in Q4 2020 [28] Market Data and Key Metrics Changes - The U.S. addressable market for the company's services is estimated to be approximately $102 billion, largely untapped [23] - A report by McKinsey suggests that up to $265 billion in medical care currently delivered in healthcare facilities will shift to home-based care by 2025 [24] - The company has provided mobile health solutions in 29 states and is licensed to operate in more [12] Company Strategy and Development Direction - The company aims to expand its mobile health and transportation services, focusing on high-quality, affordable healthcare delivery [8][10] - A notable contract with Aetna in New York and New Jersey is expected to drive future growth, providing services to over 2.5 million people [14] - The company is piloting a direct-to-consumer offering to provide cost-effective treatment alternatives for non-emergency conditions [15] - Investments in technology are seen as a significant competitive advantage, enhancing care coordination and patient experience [16][25] Management's Comments on Operating Environment and Future Outlook - Management anticipates a conservative approach to COVID testing revenue, projecting no revenue from it after Q2 2022 [7][42] - Demand for services remains strong, particularly due to staffing shortages in hospitals and healthcare systems [46][48] - The company expects to achieve fiscal 2022 revenues of approximately $400 million to $420 million, representing a 26% to 32% increase over 2021 [7][33] Other Important Information - The company hired over 900 new employees in Q4 2021, totaling over 2,300 hires for the year [32] - Cash and cash equivalents totaled $175.5 million as of December 30, 2021, with minimal debt of approximately $2 million [32] Q&A Session Summary Question: Growth rate and catalysts for mobile transport - Management indicated that growth in transportation is dependent on securing new licenses, with expectations of 35% to 40% growth per year [35][36] Question: Guidance on gross margin - Management expects gross margins to improve over time, targeting 51% to 52% for mobile health and 40% to 43% for transportation [38][52] Question: COVID revenue assumptions for 2022 - Management anticipates COVID testing revenue to drop to zero by July 1, 2022, with a conservative approach to forecasting [42][86] Question: Demand environment and staffing shortages - Management noted strong demand due to staffing shortages in healthcare systems, with a focus on providing services without adding strain to existing staff [46][48] Question: Visibility into 2022 revenue - Management outlined a five-point process for revenue guidance, considering existing contracts, pipeline contracts, and market expansion [58][63]

[Report Information](index=1&type=section&id=Report%20Information) This section provides key filing details for DocGo Inc.'s 2021 annual report, including its SEC submission, Nasdaq listings, and company classifications [Form 10-K Details](index=1&type=section&id=Form%2010-K%20Details) This report is DocGo Inc.'s annual report for the fiscal year ended December 31, 2021, filed with the SEC, listed on Nasdaq, and classified as a non-accelerated filer, smaller reporting company, and emerging growth company - DocGo Inc.'s annual report filing date is **December 31, 2021**, submitted to the SEC[2](index=2&type=chunk) - As of June 30, 2021, the aggregate market value of voting and non-voting common stock held by non-affiliates was approximately **$114.31 million**. As of March 14, 2022, the company had **100,174,275 shares of common stock outstanding**[6](index=6&type=chunk)[7](index=7&type=chunk) Employee Composition as of December 31, 2021 | Indicator | Detail | | :--- | :--- | | Trading Symbol (Common Stock) | DCGO | | Trading Symbol (Redeemable Warrants) | DCGOW | | Listing Exchange | Nasdaq Stock Market LLC | | Well-Known Seasoned Issuer | No | | Required to File Reports | No | | All Reports Filed | No | | Interactive Data File Submitted | Yes | | Filer Type | Non-Accelerated Filer, Smaller Reporting Company, Emerging Growth Company | [Documents Incorporated by Reference](index=2&type=section&id=Documents%20Incorporated%20by%20Reference) Portions of this annual report are supplemented by reference to the company's proxy statement for the 2022 Annual Meeting of Stockholders, to be filed with the SEC within 120 days after the fiscal year ended December 31, 2021 - Portions of the company's proxy statement for the 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this 10-K report, to be filed within 120 days after the 2021 fiscal year-end[9](index=9&type=chunk) [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This section provides a comprehensive list of all chapters and sub-sections within the annual report, facilitating navigation [Cautionary Note Regarding Forward-Looking Statements](index=4&type=section&id=Cautionary%20Note%20Regarding%20Forward-Looking%20Statements) This annual report contains forward-looking statements concerning the company's business and financial plans, strategies, and prospects, which are subject to risks and uncertainties that may cause actual results to differ materially from expectations - Forward-looking statements in this report are based on management's beliefs and assumptions but are subject to risks, uncertainties, and assumptions, which may cause actual results to differ materially from expectations[12](index=12&type=chunk) - The company does not undertake to publicly update or revise any forward-looking statements due to new information, future events, or otherwise[13](index=13&type=chunk) [Risk Factors Summary](index=5&type=section&id=Risk%20Factors%20Summary) This section outlines the principal risks that could materially affect DocGo's business, financial condition, and operational results [Risks Relating to the Ownership of DocGo Securities](index=5&type=section&id=Risks%20Relating%20to%20the%20Ownership%20of%20DocGo%20Securities) Ownership of DocGo securities faces risks including potential stock price decline from future sales, Nasdaq delisting, warrant exercise dilution, and warrants expiring worthless or having terms modified - Future stock sales or market expectations of future sales could cause the market price of common stock to decline[15](index=15&type=chunk) - Nasdaq may delist DocGo's securities, limiting investors' ability to trade and increasing trading restrictions[16](index=16&type=chunk) - The exercise of warrants will increase the number of shares available for future resale, resulting in dilution to existing shareholders[16](index=16&type=chunk) - Warrants may never be in-the-money, could expire worthless, and their terms may be modified with holder approval, to the detriment of holders[16](index=16&type=chunk) - The market price and trading volume of common stock and warrants may fluctuate, and if analysts cease publishing research reports, the stock price and trading volume could significantly decline[17](index=17&type=chunk) [Risks Related to DocGo's Business and Industry](index=5&type=section&id=Risks%20Related%20to%20DocGo's%20Business%20and%20Industry) DocGo's business faces risks from COVID-19, limited operating history, sustained losses, growth management, high customer acquisition costs, rising labor and insurance expenses, reliance on partners and government contracts, and IT system failures - The COVID-19 pandemic has had a material impact on DocGo's business[18](index=18&type=chunk) - DocGo has a limited operating history, which may make it difficult to evaluate its business, and it may not be successful[18](index=18&type=chunk) - DocGo has a history of losses and expects operating expenses to increase significantly in the future, and it may not achieve or maintain profitability[19](index=19&type=chunk) - If DocGo fails to manage its growth effectively, its financial results and future prospects will be adversely affected[19](index=19&type=chunk) - DocGo incurs significant upfront costs in customer relationships, and if it fails to maintain and grow these relationships or recover costs, its business will be adversely affected[20](index=20&type=chunk) - DocGo's labor costs are significant, and if it cannot control these costs, its business will be adversely affected[20](index=20&type=chunk) - DocGo's insurance costs are significant and rapidly increasing, and if it cannot obtain reasonably priced insurance or control losses, its business will be adversely affected[21](index=21&type=chunk) - DocGo relies on contractual relationships with healthcare provider partners and other strategic alliances, which could adversely affect its business[21](index=21&type=chunk) - DocGo relies on government contracts, which could adversely affect its business[22](index=22&type=chunk) - A significant portion of recent revenue growth has come from a few large customers, with the two largest customers accounting for **26% and 24% of total revenue in 2021**, respectively[23](index=23&type=chunk)[24](index=24&type=chunk) - DocGo's business relies on complex IT systems, and any failure to maintain them could have an adverse effect[26](index=26&type=chunk) - DocGo's platform is highly technical, and if it fails to operate effectively, its business could be adversely affected[27](index=27&type=chunk) - DocGo must comply with health information transmission, security, and privacy laws[28](index=28&type=chunk) - Security breaches, data loss, and other disruptions could expose sensitive information or prevent DocGo from accessing critical information, and subject it to liability[29](index=29&type=chunk) - If DocGo fails to successfully develop new products and technologies, or adapt to rapidly changing technology and industry standards or regulatory requirements, its business could be adversely affected[30](index=30&type=chunk) - DocGo is subject to federal, state, and local laws and regulations, including labor laws, and non-compliance or changes in laws could adversely affect its business[30](index=30&type=chunk) - Motion's previously restated financial statements and material weaknesses in internal control could lead to litigation or other disputes[30](index=30&type=chunk) [PART I](index=7&type=section&id=PART%20I) This part details DocGo's business operations, including services, merger, human capital, competition, intellectual property, and regulatory environment [Item 1. Business](index=7&type=section&id=Item%201.%20Business) DocGo provides high-quality, cost-effective on-demand medical mobility solutions and "last-mile" care services through its proprietary AI technology platform and a network of medical professionals across 26 states and the UK - DocGo provides on-demand medical mobility solutions and "last-mile" care services through its proprietary AI technology platform and a network of medical professionals across 26 states and the UK[34](index=34&type=chunk) - The company's mission is to transform medical transportation and mobile healthcare, offering more accessible, affordable, and efficient patient-centered out-of-hospital care[35](index=35&type=chunk) - DocGo completed its business combination with Motion Acquisition Corp. on **November 5, 2021**, and was renamed DocGo Inc[42](index=42&type=chunk) [Our Company](index=7&type=section&id=Our%20Company) Established in 2015, DocGo leverages an AI-driven proprietary technology platform and a network of medical professionals across 26 states and the UK to deliver on-demand medical mobility and "last-mile" care services - DocGo, founded in **2015**, provides on-demand medical mobility solutions and "last-mile" care services through its AI-driven proprietary technology platform and a network of over **4,000 medical professionals**[34](index=34&type=chunk)[35](index=35&type=chunk) - The company has completed over **6.2 million patient interactions**, aiming to transform medical transportation and mobile healthcare into more accessible, affordable, and efficient patient-centered out-of-hospital care[35](index=35&type=chunk) [Our Segments](index=7&type=section&id=Our%20Segments) DocGo operates through two primary segments: Transportation Services (under the Ambulnz brand), which contributed approximately 26.4% of 2021 revenue, and Mobile Health Solutions, which contributed 73.6% and is projected for significant growth - DocGo's on-demand medical mobility solutions are offered under the Ambulnz brand, including emergency and non-emergency transportation services, contributing approximately **26.4% of revenue in 2021**[36](index=36&type=chunk)[38](index=38&type=chunk) - Mobile Health Solutions provide in-home assessments, diagnostics, triage, and treatment services, contributing approximately **73.6% of revenue in 2021**, with significant growth expected due to the increasing adoption of telehealth[39](index=39&type=chunk)[40](index=40&type=chunk) - As of December 31, 2021, the company operated **294 ambulances in the U.S.** and **32 in the U.K.**[38](index=38&type=chunk) [Merger with Motion Acquisition Corp.](index=9&type=section&id=Merger%20with%20Motion%20Acquisition%20Corp.) DocGo Inc., formerly Motion Acquisition Corp., completed its business combination with Ambulnz, Inc. on November 5, 2021, making Ambulnz a wholly-owned subsidiary and securing $158 million in net financing - DocGo Inc. (formerly Motion Acquisition Corp.) completed its business combination with Ambulnz, Inc. on **November 5, 2021**, with Ambulnz becoming a wholly-owned subsidiary of DocGo[42](index=42&type=chunk) - Following the merger, the company raised **$158 million in net proceeds** through Motion's trust account and PIPE financing, after deducting **$20 million in transaction costs**[43](index=43&type=chunk) [Human Capital Resources](index=9&type=section&id=Human%20Capital%20Resources) As of December 31, 2021, DocGo employed over 2,900 individuals, including medical professionals and support staff, and engaged an additional 2,100 through subcontractors, focusing on talent attraction and retention through compensation and training - The company also employed approximately **2,100 personnel** through subcontracted labor agencies, primarily in medical professional roles[45](index=45&type=chunk) - DocGo offers an industry-leading compensation model, including base hourly wages, performance-based bonuses, health insurance, paid time off, and an equity incentive plan for frontline clinicians, to attract and retain high-quality talent[48](index=48&type=chunk)[49](index=49&type=chunk) - The company established DocGo Academy and DocGo EMS Academy, providing free training and career development opportunities to cultivate and attract medical professionals[50](index=50&type=chunk)[56](index=56&type=chunk) Employee Composition as of December 31, 2021 | Category | Full-Time | Part-Time | Total | | :--- | :--- | :--- | :--- | | Medical Professionals | 1295 | 1205 | 2500 | | Field Management | 169 | 9 | 178 | | Corporate Support | 242 | 4 | 246 | | **Total** | **1706** | **1218** | **2924** | [Competition](index=11&type=section&id=Competition) DocGo operates in a highly competitive U.S. healthcare industry, facing competition in medical mobility and "last-mile" solutions from local providers, national organizations, and large tech companies, based on service quality, pricing, and technology - DocGo faces intense competition in the medical transportation and "last-mile" healthcare solutions markets from small local providers, large national organizations (e.g., Rural/Metro Corporation, AMR), and potentially large technology companies (e.g., Apple, Amazon) and retailers (e.g., Walmart, CVS)[58](index=58&type=chunk)[59](index=59&type=chunk)[60](index=60&type=chunk) - Competition in the medical transportation industry is based on customer service, clinical care, employee recruitment and training, pricing, billing and reimbursement expertise[59](index=59&type=chunk) - Competition in the telehealth industry is based on scale, ease of use, convenience and accessibility, brand recognition, breadth, depth, and effectiveness of services, technology, clinical quality, customer support, cost, reputation, and customer satisfaction and value[60](index=60&type=chunk) [Intellectual Property](index=11&type=section&id=Intellectual%20Property) DocGo's intellectual property, including its proprietary platform, mobile applications, trademarks, and patents, is protected through copyrights, trademarks, patents, trade secrets, licensing, and confidentiality agreements - DocGo's intellectual property includes website content, proprietary platforms, mobile applications, registered domain names, software code, firmware, hardware designs, registered and unregistered trademarks, copyrights, trade secrets, inventions, and patent applications[61](index=61&type=chunk) - The company protects its intellectual property through copyrights, trademarks, patents, trade secrets, intellectual property licenses, and contractual rights, including confidentiality agreements[62](index=62&type=chunk) - The Ambulnz trademark and company logo are registered in the U.S. and U.K., while the DocGo trademark and design are registered in the U.K., and the DocGo trademark is being registered in the U.S.[62](index=62&type=chunk) [Regulation](index=11&type=section&id=Regulation) DocGo's operations are extensively regulated by federal, state, local, and international laws, including the False Claims Act, HIPAA, anti-kickback statutes, Stark Law, and corporate practice of medicine prohibitions, with non-compliance carrying significant penalties - DocGo's operations are extensively regulated by federal, state, local, and international jurisdictions, with laws and regulations constantly evolving and potentially becoming more stringent[63](index=63&type=chunk) - The Federal False Claims Act imposes civil and criminal liability for submitting false or fraudulent claims to the federal government, including substantial fines and treble damages[65](index=65&type=chunk) - The Health Insurance Portability and Accountability Act (HIPAA) and its amendments establish criminal penalties for healthcare fraud and false statements, and set privacy and security standards for protected health information (PHI)[69](index=69&type=chunk) - The Federal Anti-Kickback Statute prohibits offering or accepting any form of remuneration to induce referrals or services covered by federal healthcare programs (e.g., Medicare, Medicaid)[71](index=71&type=chunk) - The Federal Stark Law prohibits physicians from referring Medicare patients for designated health services to entities with which they have a financial relationship, unless an exception applies, and is a strict liability statute[72](index=72&type=chunk) - Many states prohibit general business corporations (like DocGo) from practicing medicine, controlling physicians' medical decisions, or sharing professional fees with physicians[73](index=73&type=chunk)[81](index=81&type=chunk) - International operations are subject to different and potentially more stringent laws and regulations, including anti-corruption laws (e.g., FCPA, UK Bribery Act 2010), economic sanctions laws, and various privacy, insurance, tax, and trade laws and regulations[83](index=83&type=chunk)[85](index=85&type=chunk)[88](index=88&type=chunk) [Available Information](index=16&type=section&id=Available%20Information) DocGo provides free electronic copies of its SEC filings, including Form 10-K, 10-Q, and 8-K reports and amendments, on the "Investors" section of its website, www.DocGo.com - DocGo provides free electronic copies of its Form 10-K, 10-Q, and 8-K reports and amendments filed with the SEC on the "Investors" section of its website, www.DocGo.com[91](index=91&type=chunk) [Item 1A. Risk Factors](index=17&type=section&id=Item%201A.%20Risk%20Factors) DocGo faces risks from business strategy failures, over-reliance on partners and government contracts, high customer acquisition costs, acquisition integration challenges, COVID-19 impacts, intense competition, key client loss, rising labor costs, and IT system failures - DocGo's future financial performance and success largely depend on its ability to successfully implement its business strategy, including developing new healthcare provider partnerships, expanding existing ones, pursuing organic growth, making selective acquisitions, and improving operational efficiency and productivity[93](index=93&type=chunk) - DocGo's business growth heavily relies on its acquisition strategy, which involves significant risks such as business integration, unforeseen liabilities, asset impairment, additional debt, or equity dilution[100](index=100&type=chunk)[102](index=102&type=chunk) - The COVID-19 pandemic adversely affected DocGo's medical transportation business but significantly increased demand for remote and mobile testing and vaccination services, with **COVID testing-related revenue reaching approximately $110 million in 2021**[108](index=108&type=chunk)[111](index=111&type=chunk) - DocGo's labor costs are its largest fixed cost, accounting for **25.1% of revenue in 2021** and **59.9% in 2020**[125](index=125&type=chunk) - DocGo's business and competitive advantage depend on the performance and reliability of its technology platform; any system outages, failures, or reliance on third-party mobile operating systems and app marketplaces could adversely affect its business[155](index=155&type=chunk)[156](index=156&type=chunk)[159](index=159&type=chunk) - DocGo heavily relies on information technology networks and systems to securely process, transmit, and store sensitive data; security breaches, data loss, or other disruptions could harm its reputation, lead to legal liability, and financial losses[164](index=164&type=chunk)[168](index=168&type=chunk)[169](index=169&type=chunk) - As an "emerging growth company," DocGo can utilize certain exemptions, such as not requiring an auditor attestation report on internal controls, which may make its stock less attractive to some investors[137](index=137&type=chunk)[300](index=300&type=chunk)[302](index=302&type=chunk) [Risks Related to DocGo's Business Strategy](index=17&type=section&id=Risks%20Related%20to%20DocGo's%20Business%20Strategy) DocGo's business strategy faces risks of failed implementation, including inability to develop customer relationships, expand markets, launch new services, or achieve operational efficiencies, alongside high reliance on contractual partners and acquisition integration challenges - DocGo's business strategy includes developing new healthcare provider partnerships, expanding existing ones, leveraging organic growth opportunities, making selective acquisitions, and improving operational efficiency and productivity, but its successful implementation is uncertain[93](index=93&type=chunk)[94](index=94&type=chunk) - DocGo heavily relies on contractual relationships with healthcare provider partners, which may pose commercial and regulatory risks, such as the contract with Fresenius contributing approximately **7.1% of revenue in 2021**[95](index=95&type=chunk)[96](index=96&type=chunk) - DocGo's growth strategy relies on acquisitions, but acquisitions involve significant risks such as business integration, unforeseen liabilities, asset impairment, additional debt or equity dilution, and may divert management's attention[100](index=100&type=chunk)[102](index=102&type=chunk)[104](index=104&type=chunk) [Risks Related to DocGo's Business and Industry](index=20&type=section&id=Risks%20Related%20to%20DocGo's%20Business%20and%20Industry) DocGo's business faces challenges from COVID-19's mixed impact on transportation and mobile health, intense industry competition, key customer loss, government contract dependency, rising labor costs, and difficulties in accounts receivable collection - The COVID-19 pandemic adversely affected DocGo's medical transportation business but significantly increased demand for remote and mobile testing and vaccination services, with **COVID testing-related revenue reaching approximately $110 million in 2021**[108](index=108&type=chunk)[111](index=111&type=chunk) - The medical transportation and telehealth industries are highly competitive, with DocGo facing competition from government entities, hospitals, local and national providers, and large technology companies[116](index=116&type=chunk)[117](index=117&type=chunk) - A significant portion of DocGo's revenue growth comes from a few large customers, with the two largest customers contributing **26% and 24% of total sales in 2021**, respectively, and these contracts are often terminable at will, posing a risk of customer loss[123](index=123&type=chunk) - DocGo's labor costs are its largest fixed cost, accounting for **25.1% of revenue in 2021** and **59.9% in 2020**; labor shortages and union activities could lead to further cost increases[125](index=125&type=chunk)[127](index=127&type=chunk) - The company faces risks of difficulties in accounts receivable collection, unfavorable changes in payer mix, and failure to accurately assess the costs of new revenue opportunities[128](index=128&type=chunk)[129](index=129&type=chunk) [Risks Related to DocGo's Limited Operating History](index=26&type=section&id=Risks%20Related%20to%20DocGo's%20Limited%20Operating%20History) DocGo's limited operating history since 2015 makes business evaluation difficult, and it faces inherent risks of an early-stage company, including sustained losses, increased operating expenses, and pressure from rapid growth - DocGo has a limited operating history since its founding in **2015**, making it difficult to evaluate its business and prospects, and it faces risks inherent in an early-stage company, including financing needs, commercialization challenges, market acceptance, regulatory issues, and competition[142](index=142&type=chunk) - DocGo incurred net losses annually before achieving **net income of $19.2 million in 2021**, with accumulated deficits of **$63.6 million as of December 31, 2021**, and expects significantly increased operating expenses, potentially failing to achieve or maintain profitability[144](index=144&type=chunk)[145](index=145&type=chunk) - DocGo's rapid growth (revenue from **$30.9 million in 2017 to $318.7 million in 2021**, and over **2,900 employees**) places significant strain on management, operations, and financial infrastructure, which could adversely affect its business, financial condition, and operating results if not effectively managed[146](index=146&type=chunk)[147](index=147&type=chunk)[149](index=149&type=chunk) [Risks Related to Technology](index=28&type=section&id=Risks%20Related%20to%20Technology) DocGo's business relies heavily on complex IT systems and its proprietary technology platform, making it vulnerable to system failures, internet disruptions, and data security breaches, which could lead to reputational damage, legal liability, and financial losses - DocGo's business relies on complex IT systems and a proprietary technology platform; any system outages, failures, or maintenance issues could affect resource allocation, billing processes, and customer satisfaction[151](index=151&type=chunk)[153](index=153&type=chunk) - The functionality and reliability of the company's technology platform depend on internet and mobile infrastructure, as well as third-party mobile operating systems and app marketplaces; any disruptions or compatibility issues could adversely affect its business[155](index=155&type=chunk)[156](index=156&type=chunk)[159](index=159&type=chunk) - DocGo relies on third-party service providers and software, including open-source software, which may lead to service interruptions, data loss, increased costs, and intellectual property infringement or compliance risks[160](index=160&type=chunk)[161](index=161&type=chunk)[163](index=163&type=chunk) - Data security breaches, loss of sensitive business, customer, or patient information (including PHI and PII), or unauthorized access could result in reputational harm, legal liability, high remediation costs, and financial losses[164](index=164&type=chunk)[168](index=168&type=chunk)[169](index=169&type=chunk) [Other Risks Related to DocGo's Business](index=32&type=section&id=Other%20Risks%20Related%20to%20DocGo's%20Business) DocGo's success depends on retaining key personnel and medical professionals, faces intellectual property risks, and must adapt to technological changes. It also faces litigation, regulatory compliance, insurance, capital expenditure, international operation, and tax risks - DocGo's success largely depends on the contributions of key management personnel (e.g., founder Stan Vashovsky) and its ability to recruit, train, and retain qualified medical professionals; personnel turnover could adversely affect operations[171](index=171&type=chunk)[172](index=172&type=chunk)[173](index=173&type=chunk) - The company faces risks of failing to protect or enforce its intellectual property rights, as well as claims of infringing others' proprietary technology or intellectual property, which could lead to costly litigation and management distraction[174](index=174&type=chunk)[177](index=177&type=chunk)[178](index=178&type=chunk)[180](index=180&type=chunk) - DocGo's marketing efforts (including a brand relaunch in **January 2021**) may be ineffective, and failure to successfully develop new products and technologies or adapt to rapidly changing technology and industry standards could adversely affect its business[181](index=181&type=chunk)[183](index=183&type=chunk)[185](index=185&type=chunk)[186](index=186&type=chunk) - The company may face litigation risks from medical malpractice, vehicle collisions, patient care incidents, employee injuries, billing practices, and employment disputes, and insurance coverage and reserves may be insufficient to cover all losses[187](index=187&type=chunk)[188](index=188&type=chunk)[193](index=193&type=chunk)[194](index=194&type=chunk) - DocGo's international operations (e.g., in the U.K.) face additional regulatory, economic, political, and cultural risks; natural disasters, war, terrorism, and cybersecurity incidents could also materially adversely affect the business[196](index=196&type=chunk)[198](index=198&type=chunk)[199](index=199&type=chunk)[201](index=201&type=chunk) - As of December 31, 2021, DocGo had approximately **$56.6 million in federal net operating loss carryforwards** and approximately **$67.2 million in state net operating loss carryforwards**, but their utilization may be limited due to ownership changes[202](index=202&type=chunk) - Changes in tax laws (e.g., increased U.S. corporate income tax rates) or unexpected tax liabilities could adversely affect DocGo's effective income tax rate and profitability, and changes in accounting rules and interpretations could significantly impact financial statements[204](index=204&type=chunk)[205](index=205&type=chunk) - DocGo's internal controls may be ineffective, and its independent registered public accounting firm may not be able to attest to their effectiveness, which could affect the accuracy and timeliness of financial reporting[206](index=206&type=chunk)[208](index=208&type=chunk) - Motion's prior material weaknesses in internal control over financial reporting (e.g., misclassification of warrants and Class A common stock) could lead to litigation or other disputes and adversely affect the company's business, operating results, and financial condition[209](index=209&type=chunk)[212](index=212&type=chunk)[213](index=213&type=chunk)[215](index=215&type=chunk) [Risks Related to Healthcare Regulation](index=39&type=section&id=Risks%20Related%20to%20Healthcare%20Regulation) DocGo operates in a highly regulated healthcare industry, requiring compliance with complex federal and state laws like the False Claims Act, HIPAA, and anti-kickback statutes, with non-compliance leading to significant penalties and operational disruptions - DocGo operates in the highly regulated U.S. healthcare industry and must comply with federal and state laws and regulations, including the False Claims Act, HIPAA, anti-kickback statutes, Stark Law, and corporate practice of medicine prohibitions[217](index=217&type=chunk)[218](index=218&type=chunk)[220](index=220&type=chunk) - Failure to comply with these laws and regulations could result in civil or criminal penalties, fines, recoupment of overpayments, license revocation, exclusion from government healthcare programs, and potential litigation and negative publicity[223](index=223&type=chunk)[224](index=224&type=chunk) - Telehealth industry laws and regulations are still evolving, and relaxed restrictions during the COVID-19 pandemic may be reinstated or modified, adversely affecting DocGo's telehealth services[237](index=237&type=chunk)[238](index=238&type=chunk) - DocGo must properly enroll in government healthcare programs to receive reimbursement for services, and expansion into new markets may cause enrollment delays. Reductions in Medicare and Medicaid reimbursement rates or changes in rules could materially adversely affect DocGo's revenue and operating results[240](index=240&type=chunk)[242](index=242&type=chunk)[246](index=246&type=chunk)[248](index=248&type=chunk)[250](index=250&type=chunk)[253](index=253&type=chunk) - The company may be subject to federal and state investigations and compliance reviews, which could lead to significant expenses, negative publicity, and management distraction, potentially resulting in fines and penalties[254](index=254&type=chunk) - DocGo's business practices could be deemed illegal fee-splitting or corporate practice of medicine, potentially leading to penalties, contract invalidation, or requiring restructuring of contractual arrangements[256](index=256&type=chunk)[258](index=258&type=chunk) [Additional Risks Relating to Ownership of Common Stock and Warrants](index=46&type=section&id=Additional%20Risks%20Relating%20to%20Ownership%20of%20Common%20Stock%20and%20Warrants) Ownership of DocGo's common stock and warrants faces risks including Nasdaq delisting, lack of cash dividends, analyst coverage impact, future stock sales or warrant exercise dilution, anti-takeover provisions, and potential warrant redemption or modification - Nasdaq may delist DocGo's securities, which could result in limited market quotations, reduced liquidity, designation as a "penny stock," and limited future financing capabilities[261](index=261&type=chunk)[263](index=263&type=chunk) - DocGo currently does not intend to pay cash dividends in the foreseeable future, and investor returns will depend on selling common stock for a price greater than the purchase price[266](index=266&type=chunk)[267](index=267&type=chunk) - Future stock sales or expectations of future sales, as well as warrant exercises, could lead to a decline in the market price of common stock and dilution of existing shareholders' equity[271](index=271&type=chunk)[275](index=275&type=chunk)[290](index=290&type=chunk)[291](index=291&type=chunk) - Anti-takeover provisions in DocGo's charter may delay or prevent a change of control, limiting shareholders' ability to receive a premium[279](index=279&type=chunk)[281](index=281&type=chunk) - DocGo may redeem unexpired warrants at an unfavorable time, causing them to become worthless; warrant terms may also be modified with holder approval, to the detriment of holders[288](index=288&type=chunk)[289](index=289&type=chunk)[292](index=292&type=chunk)[293](index=293&type=chunk) - The market price and trading volume of common stock and warrants may fluctuate due to various factors, including company performance, analyst expectations, changes in key personnel, market disruptions, and macroeconomic conditions[295](index=295&type=chunk) [Item 1B. Unresolved Staff Comments](index=51&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) This report does not contain any unresolved staff comments - No unresolved staff comments are mentioned in this report[304](index=304&type=chunk) [Item 2. Properties](index=51&type=section&id=Item%202.%20Properties) DocGo's headquarters are in New York City, with 26 leased or owned office locations across 26 U.S. states and the UK, primarily for ambulance parking, garages, maintenance, and administration - DocGo's headquarters are in New York City, and it leases or owns office facilities in the U.S. (**26 locations**) and the U.K. (**3 locations**), primarily for administrative, sales, marketing, ambulance parking, garages, and maintenance[305](index=305&type=chunk) - As of December 31, 2021, the company operated **482 vehicles**, including **294 ambulances**, **85 wheelchair vans**, and **103 basic transport or support vehicles**[307](index=307&type=chunk) - Approximately **47% of the company's fleet is leased**, and **53% is owned**, with the existing ambulance fleet having an average age of approximately **four years**[307](index=307&type=chunk) [Item 3. Legal Proceedings](index=52&type=section&id=Item%203.%20Legal%20Proceedings) DocGo is involved in legal proceedings, claims, and investigations in its ordinary course of business, with potential losses disclosed and accrued according to accounting standards - DocGo is involved in legal proceedings, claims, and investigations in its ordinary course of business, and potential losses are disclosed and accrued according to accounting standards[309](index=309&type=chunk)[310](index=310&type=chunk) - Management believes the company has adequate legal defenses for all legal proceedings, and the outcomes will not have a material adverse effect on the consolidated financial statements[309](index=309&type=chunk) [Item 4. Mine Safety Disclosures](index=52&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Mine safety disclosures are not applicable to this report - Mine safety disclosures are not applicable to this report[311](index=311&type=chunk) [PART II](index=53&type=section&id=PART%20II) This part covers DocGo's common stock market, stockholder matters, management's financial discussion, and financial statements [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=53&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) DocGo's common stock and warrants trade on the Nasdaq Capital Market under "DCGO" and "DCGOW," respectively, with 103 common stockholders and 2 warrant holders as of March 11, 2022, and no cash dividends paid to date - DocGo's common stock and warrants trade on the Nasdaq Capital Market under the symbols **"DCGO"** and **"DCGOW,"** respectively[314](index=314&type=chunk) - As of **March 11, 2022**, the company had **103 holders of common stock** and **2 holders of warrants**[315](index=315&type=chunk) - The company has not paid cash dividends to date, and future dividend payments will be determined by the Board of Directors based on factors such as the company's earnings, capital needs, and financial condition[316](index=316&type=chunk) [Item 6. Reserved](index=54&type=section&id=Item%206.%20Reserved) This item is reserved - This item is reserved[318](index=318&type=chunk) [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=55&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section discusses DocGo's financial condition and operating results for the fiscal year ended December 31, 2021, highlighting its business overview, COVID-19 impact, revenue and expense components, and liquidity - DocGo is a medical transportation and mobile health services company, utilizing proprietary dispatch and communication technology to provide high-quality medical transportation and in-home healthcare services in major metropolitan areas across the U.S. and U.K.[320](index=320&type=chunk) - The company's revenue is primarily derived from two operating segments: Transportation Services (including emergency response and non-emergency transport) and Mobile Health Services (including in-home and in-office services, COVID-19 testing, and event services)[321](index=321&type=chunk)[322](index=322&type=chunk) - The COVID-19 pandemic had a complex impact on the company's business: ambulance transport volumes decreased, but demand for mobile health services (especially COVID-19 testing and vaccinations) significantly increased, with **Mobile Health revenue reaching $234.4 million in 2021**, compared to **$30.9 million in 2020**[325](index=325&type=chunk)[327](index=327&type=chunk)[330](index=330&type=chunk) - Factors affecting the company's operating results include obtaining operating licenses, acquisition strategy, market conditions for healthcare transportation and mobile health services, overall economic environment, availability of medical professionals, labor costs, supplier production schedules, inflation, and R&D investments[332](index=332&type=chunk)[333](index=333&type=chunk)[334](index=334&type=chunk)[335](index=335&type=chunk)[337](index=337&type=chunk)[340](index=340&type=chunk)[341](index=341&type=chunk)[342](index=342&type=chunk)[343](index=343&type=chunk) - The company expects its existing cash and cash equivalents, anticipated future cash flows from operations, and available credit facilities to be sufficient to meet its operating needs for at least the next twelve months[374](index=374&type=chunk) 2021 vs 2020 Net Income/Loss | Indicator | 2021 (Millions USD) | 2020 (Millions USD) | | :--- | :--- | :--- | | Net Income/(Loss) | 19.2 | (14.8) | [Overview](index=55&type=section&id=Overview) DocGo, founded in 2015, is a medical transportation and mobile services company that uses proprietary technology to provide high-quality medical transport and in-home care in major U.S. and UK metropolitan areas - DocGo, founded in **2015**, is a medical transportation and mobile services company that utilizes proprietary dispatch and communication technology to provide high-quality medical transportation and in-home healthcare services in major metropolitan areas across the U.S. and U.K.[320](index=320&type=chunk) - The company's revenue is primarily derived from two operating segments: Transportation Services (including emergency response and non-emergency transport) and Mobile Health Services (including in-home and in-office services, COVID-19 testing, and event services)[321](index=321&type=chunk)[322](index=322&type=chunk) [COVID-19 Impact](index=55&type=section&id=COVID-19%20Impact) COVID-19 had a mixed impact on DocGo, reducing non-emergency transport but significantly boosting mobile health services, with 2021 mobile health revenue reaching $234.4 million, accelerating business diversification despite ongoing uncertainties - The COVID-19 pandemic negatively impacted DocGo's non-emergency medical transportation business, but by **December 2021**, transport volumes had increased by **27.2%** compared to March 2020[325](index=325&type=chunk) - The company achieved significant growth in mobile health through participation in FEMA emergency programs and expansion of Rapid Reliable Testing (RRT) services, with **Mobile Health revenue reaching $234.4 million in 2021**, compared to **$30.9 million in 2020**[326](index=326&type=chunk)[327](index=327&type=chunk) - The company received approximately **$1 million in Public Health and Social Services Emergency Fund payments** and approximately **$2.4 million in accelerated Medicare payments in 2020**, of which **$1.7 million was recouped by Medicare by December 31, 2021**[329](index=329&type=chunk) - The pandemic accelerated the company's business diversification towards mobile health services, but the long-term sustainability of the pandemic's ongoing impact and related revenue (especially COVID-19 testing and vaccinations) remains uncertain[330](index=330&type=chunk)[331](index=331&type=chunk) [Factors Affecting Our Results of Operations](index=57&type=section&id=Factors%20Affecting%20Our%20Results%20of%20Operations) DocGo's operating results are influenced by factors such as operating license acquisition, acquisition strategy, healthcare market conditions, economic environment, medical professional availability, labor costs, inflation, R&D investment, and the regulatory landscape - Operating Licenses: New license approvals are lengthy, and the company mitigates risk by acquiring existing businesses and licenses[332](index=332&type=chunk) - Acquisitions: Historical growth has been partly achieved through acquisitions, and future expansion will continue through acquisitions to broaden geographic reach and enhance value[333](index=333&type=chunk) - Healthcare Services Market: The transportation services market relies on surgeries and medical procedures; transport volumes decreased during the pandemic, but the company reallocated assets to meet changing demand[334](index=334&type=chunk) - Overall Economic Conditions: National and local economic changes, such as demographics, healthcare coverage, and interest rates, affect financial performance[335](index=335&type=chunk) - Trip Volume and Average Trip Price: Trip volume is a key indicator of demand for transportation services, and average trip price reflects service compensation rates. The average trip price increased in 2021 due to changes in service mix, and Medicare reimbursement rate increases are expected to further boost prices in 2022[337](index=337&type=chunk)[338](index=338&type=chunk) - Cost Control Capability: Labor, medical supplies, and vehicle-related costs are major expenses, and the company uses proprietary technology to improve productivity and optimize labor costs[339](index=339&type=chunk) - Inflation: Inflation rates rose significantly in 2021, leading to increased wages, fuel, and medical supply costs, compressing gross margins, and 2022 inflation is expected to exceed the past decade's levels[340](index=340&type=chunk)[341](index=341&type=chunk) - R&D Investment and Customer Experience: Continuous investment in R&D, innovative software services, and mobile applications is crucial for maintaining market position and revenue growth[342](index=342&type=chunk) - Regulatory Environment: The company's business is subject to federal, state, and local laws and regulations (including healthcare and emergency medical services laws), and any significant changes could affect operations and costs[343](index=343&type=chunk) [Components of Results of Operations](index=59&type=section&id=Components%20of%20Results%20of%20Operations) DocGo's operating results are segmented into Transportation Services and Mobile Health Services, with revenue from both, and costs primarily comprising employee wages, vehicle expenses, and subcontractor fees, alongside various operating expenses - DocGo's business consists of two reportable segments: Transportation Services and Mobile Health Services, with performance evaluated based on the operating results of each segment[345](index=345&type=chunk) - Revenue: Derived from ambulance transportation and mobile health services[346](index=346&type=chunk) - Cost of Revenue: Primarily includes employee wages, vehicle insurance, maintenance, fuel, lab fees, facility rent, medical supplies, and subcontractor fees, expected to increase with revenue growth[347](index=347&type=chunk) - Operating Expenses: Include general and administrative expenses (salaries, bad debt, insurance, consulting fees, professional services), expected to increase with business growth and public company operations[348](index=348&type=chunk) - Depreciation and Amortization: Asset depreciation uses the straight-line method, and intangible assets are amortized over their useful lives[349](index=349&type=chunk) - Legal and Regulatory: Includes legal fees, healthcare compliance consulting fees, claims processing fees, and legal settlement costs[350](index=350&type=chunk) - Technology and Development: Primarily for proprietary technology design and development, third-party software, and technology, expected to increase in the future to support growth[351](index=351&type=chunk) - Sales, Advertising, and Marketing: Includes sales commissions, marketing programs, trade shows, and promotional materials, expected to increase with marketing activities and business expansion[352](index=352&type=chunk) - Interest Expense: Primarily from interest on outstanding notes and financing obligations[353](index=353&type=chunk) [Results of Operations (Comparison of Fiscal 2021 with Fiscal 2020)](index=60&type=section&id=Results%20of%20Operations%20(Comparison%20of%20Fiscal%202021%20with%20Fiscal%202020)) DocGo achieved significant growth in fiscal year 2021, with total revenue increasing by 239% to $318.7 million and a net profit of $19.2 million, driven primarily by a 659% increase in mobile health services revenue Comparison of Operating Results 2021 vs 2020 (Millions USD) | Indicator | 2021 | 2020 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Net Revenue | 318.7 | 94.1 | 224.6 | 239% | | Cost of Revenue | 209.0 | 62.7 | 146.3 | 233% | | Total Operating Expenses | 94.4 | 46.1 | 48.3 | 105% | | Operating Income/(Loss) | 15.4 | (14.8) | 30.2 | - | | Total Other Income (Expense) | 4.4 | 0.1 | 4.3 | 3450% | | Net Income/(Loss) | 19.2 | (14.8) | 34.0 | - | | Net Income/(Loss) Attributable to DocGo Inc. Stockholders | 23.8 | (14.4) | 38.2 | - | Revenue by Business Segment 2021 vs 2020 | Business Segment | 2021 Revenue (Millions USD) | 2020 Revenue (Millions USD) | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Transportation Services | 84.3 | 63.2 | 21.1 | 33% | | Mobile Health | 234.4 | 30.9 | 203.5 | 659% | - Transportation Services revenue growth was primarily due to a **12% increase in transport trips** and a rise in average trip price (from **$324 to $342**), along with a **135% increase in fixed-rate ambulance service revenue**[357](index=357&type=chunk) - The significant growth in Mobile Health revenue is primarily attributed to the expanded scope of services in 2021, particularly COVID-19 related testing and vaccination services[359](index=359&type=chunk) - Cost of revenue as a percentage of revenue decreased from **66.6% in 2020 to 65.6% in 2021**, but the absolute amount significantly increased due to higher compensation, subcontracted labor, lab fees, medical supplies, and vehicle costs[360](index=360&type=chunk)[361](index=361&type=chunk) - Operating expenses as a percentage of revenue decreased from **49.0% in 2020 to 29.6% in 2021**, primarily due to the substantial increase in total revenue and the semi-fixed nature of the company's infrastructure costs[364](index=364&type=chunk) - Net interest expense increased to **$0.8 million in 2021**, primarily reflecting increased payments for leased vehicles. A **$5.2 million gain** was recognized from the revaluation of warrant liabilities[368](index=368&type=chunk)[370](index=370&type=chunk) [Liquidity and Capital Resources](index=63&type=section&id=Liquidity%20and%20Capital%20Resources) DocGo primarily obtains liquidity through equity financing, including $158.1 million net proceeds from the Motion merger in 2021, and operating cash flow, expecting sufficient resources for at least the next twelve months - DocGo primarily obtains liquidity through equity financing (including **$158.1 million in net proceeds** from the merger with Motion) and operating cash flow[373](index=373&type=chunk) - As of December 31, 2021, total cash available was **$175.5 million**, an increase of **$143.1 million** from 2020, primarily reflecting proceeds from the Motion transaction[375](index=375&type=chunk) - The company expects its existing cash and cash equivalents, anticipated future cash flows from operations, and available credit facilities to be sufficient to meet its operating needs for at least the next twelve months[374](index=374&type=chunk) - Operating activities used **$1.9 million in cash in 2021**, primarily due to a **$57.1 million increase in accounts receivable**, partially offset by a **$32.6 million increase in accounts payable and accrued expenses**[378](index=378&type=chunk) - Investing activities used **$8.6 million in cash in 2021**, primarily for the acquisition of property and equipment (**$4.8 million**) and business and intangible assets (**$3.1 million**) [380](index=380&type=chunk) - Financing activities provided **$155.2 million in cash in 2021**, primarily from **$158.1 million in net proceeds** from common stock issuance related to the Motion merger[382](index=382&type=chunk) Working Capital Comparison 2021 vs 2020 (Millions USD) | Indicator | 2021-12-31 | 2020-12-31 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Current Assets | 256.0 | 58.4 | 197.6 | 338% | | Current Liabilities | 57.9 | 23.5 | 34.4 | 146% | | **Total Working Capital** | **198.1** | **34.9** | **163.2** | **468%** | Cash Flow Summary 2021 vs 2020 (Millions USD) | Cash Flow Category | 2021 | 2020 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | (1.9) | (10.7) | 8.8 | -82% | | Net Cash Flow from Investing Activities | (8.6) | (6.0) | (3.1) | 43% | | Net Cash Flow from Financing Activities | 155.2 | (0.8) | 156.5 | - | | Effect of Exchange Rate Changes | 0.0 | 0.2 | (0.2) | -100% | | Net Increase/(Decrease) in Cash | 144.7 | (17.3) | 162.0 | - | [Critical Accounting Policies](index=65&type=section&id=Critical%20Accounting%20Policies) DocGo's financial statements adhere to U.S. GAAP and SEC rules, using reverse recapitalization for the Motion merger, and key policies cover consolidation, foreign currency, estimates, credit risk, revenue recognition, and income taxes - DocGo's consolidated financial statements adhere to U.S. GAAP and SEC rules, applying reverse recapitalization accounting for the merger with Motion, with Ambulnz, Inc. treated as the accounting acquirer[387](index=387&type=chunk)[388](index=388&type=chunk)[443](index=443&type=chunk)[447](index=447&type=chunk) - The company consolidates the variable interest entity MD1 Medical Care P.C., as it has control over MD1 and bears its losses[390](index=390&type=chunk)[449](index=449&type=chunk) - Key accounting estimates include allowance for doubtful accounts, equity-based compensation, incremental borrowing rates for lease agreements, software development costs, impairment of long-lived assets, goodwill and indefinite-lived intangible assets, business combinations, reserves for self-insured losses, and income taxes[452](index=452&type=chunk) - The company had two major customers in 2021, contributing approximately **23% and 26% of revenue**, and approximately **26% and 24% of net accounts receivable**, respectively[458](index=458&type=chunk) - DocGo, as an "emerging growth company," has elected to use the extended transition period provided by the JOBS Act for complying with new or revised accounting standards[460](index=460&type=chunk)[461](index=461&type=chunk) - The company's revenue recognition follows ASC 606, treating transportation services and mobile health services as single performance obligations, with revenue recognized upon completion of the performance obligation[496](index=496&type=chunk)[497](index=497&type=chunk)[498](index=498&type=chunk)[501](index=501&type=chunk)[505](index=505&type=chunk)[506](index=506&type=chunk) Revenue by Geographic Market and Business Segment 2021 vs 2020 | Category | 2021 | 2020 | | :--- | :--- | :--- | | **Primary Geographic Markets** | | | | United States | $309,218,594 | $88,362,445 | | United Kingdom | $9,499,986 | $5,728,213 | | **Total Revenue** | **$318,718,580** | **$94,090,658** | | **Primary Segments/Service Lines** | | | | Transportation Services | $84,268,817 | $63,188,855 | | Mobile Health | $234,449,763 | $30,901,803 | | **Total Revenue** | **$318,718,580** | **$94,090,658** | [Item 7A. Quantitative and Qualitative Disclosures About Market Risk](index=67&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) DocGo, as a smaller reporting company, is not required to provide information under this item per Exchange Act Rule 12b-2 and Regulation S-K Item 10(f)(1) - DocGo, as a smaller reporting company, is not required to provide quantitative and qualitative disclosures about market risk[405](index=405&type=chunk) [Item 8. Financial Statements and Supplementary Data](index=67&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents DocGo Inc.'s consolidated financial statements, including the independent auditor's report, balance sheets, statements of operations, changes in stockholders' equity, cash flows, and comprehensive notes detailing accounting policies and financial items - This section contains the consolidated financial statements of DocGo Inc. and its subsidiaries, including the Report of Independent Registered Public Accounting Firm, Consolidated Balance Sheets, Consolidated Statements of Operations and Comprehensive Income (Loss), Consolidated Statements of Changes in Stockholders' Equity, Consolidated Statements of Cash Flows, and Notes to Consolidated Financial Statements[408](index=408&type=chunk)[409](index=409&type=chunk) - The independent registered public accounting firm, Urish Popeck & Co., LLC, issued an unqualified opinion on the consolidated financial statements as of **December 31, 2021, and 2020**[410](index=410&type=chunk) Consolidated Balance Sheets Summary (Millions USD) | Indicator | 2021-12-31 | 2020-12-31 | | :--- | :--- | :--- | | Total Assets | 309.6 | 100.2 | | Total Liabilities | 82.5 | 33.2 | | Total Equity Attributable to DocGo Inc. Stockholders | 219.6 | 55.0 | | Non-Controlling Interests | 7.5 | 11.9 | | **Total Liabilities and Stockholders' Equity** | **309.6** | **100.2** | Consolidated Statements of Operations and Comprehensive Income (Loss) Summary (Millions USD) | Indicator | 2021 | 2020 | | :--- | :--- | :--- | | Net Revenue | 318.7 | 94.1 | | Cost of Revenue | 209.0 | 62.7 | | Total Operating Expenses | 94.4 | 46.1 | | Operating Income/(Loss) | 15.4 | (14.8) | | Net Income/(Loss) | 19.2 | (14.8) | | Net Income/(Loss) Attributable to DocGo Inc. Stockholders | 23.7 | (14.4) | | Basic Net Income/(Loss) Per Share | 0.30 | (0.25) | | Diluted Net Income/(Loss) Per Share | 0.25 | (0.25) | Consolidated Statements of Cash Flows Summary (Millions USD) | Cash Flow Category | 2021 | 2020 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | (1.9) | (10.7) | | Net Cash Flow from Investing Activities | (8.6) | (6.0) | | Net Cash Flow from Financing Activities | 155.2 | (0.8) | | Net Increase/(Decrease) in Cash and Restricted Cash | 144.6 | (17.3) | [Report of Independent Registered Public Accounting Firm](index=69&type=section&id=Report%20of%20Independent%20Registered%20Public%20Accounting%20Firm) Independent registered public accounting firm Urish Popeck & Co., LLC issued an unqualified opinion on DocGo Inc.'s consolidated financial statements for 2021 and 2020, affirming fair presentation of financial position and operating results - The independent registered public accounting firm Urish Popeck & Co., LLC issued an unqualified opinion on the consolidated financial statements of DocGo Inc. and its subsidiaries as of **December 31, 2021, and 2020**[410](index=410&type=chunk) - The auditors have served as the company's auditors since **2021** and performed the audit in accordance with PCAOB standards, but did not express an opinion on the effectiveness of internal control over financial reporting[411](index=411&type=chunk)[412](index=412&type=chunk)[414](index=414&type=chunk) [Consolidated Balance Sheets](index=70&type=section&id=Consolidated%20Balance%20Sheets) As of December 31, 2021, DocGo's total assets significantly increased to $309.6 million from $100.2 million in 2020, driven by higher cash and receivables, with total liabilities rising to $82.5 million and total stockholders' equity to $227.1 million Consolidated Balance Sheets (Millions USD) | Indicator | 2021-12-31 | 2020-12-31 | | :--- | :--- | :--- | | **Assets** | | | | Cash and Cash Equivalents | $175.5 | $32.4 | | Accounts Receivable, Net | $78.4 | $24.9 | | Prepaid Expenses and Other Current Assets | $2.1 | $1.2 | | **Total Current Assets** | **$256.0** | **$58.4** | | Property and Equipment, Net | $12.7 | $9.1 | | Intangible Assets, Net | $10.7 | $10.7 | | Goodwill | $8.7 | $6.6 | | Restricted Cash | $3.6 | $2.0 | | Operating Lease Right-of-Use Assets | $4.2 | $5.0 | | Finance Lease Right-of-Use Assets | $9.3 | $7.0 | | Equity Method Investment | $0.6 | $0.0 | | Other Assets | $3.8 | $1.3 | | **Total Assets** | **$309.6** | **$100.2** | | **Liabilities and Stockholders' Equity** | | | | Accounts Payable | $15.8 | $4.0 | | Accrued Liabilities | $35.1 | $14.3 | | Line of Credit | $0.03 | $0.0 | | Notes Payable (Current) | $0.6 | $0.7 | | Due to Sellers | $1.6 | $1.1 | | Operating Lease Liabilities (Current) | $1.5 | $1.6 | | Finance Lease Liabilities (Current) | $3.3 | $1.9 | | **Total Current Liabilities** | **$57.9** | **$23.5** | | Notes Payable (Non-Current) | $1.3 | $0.6 | | Operating Lease Liabilities (Non-Current) | $3.0 | $3.6 | | Finance Lease Liabilities (Non-Current) | $6.9 | $5.5 | | Warrant Liability | $13.5 | $0.0 | | **Total Liabilities** | **$82.5** | **$33.2** | | Total Equity Attributable to DocGo Inc. Stockholders | $219.6 | $55.0 | | Non-Controlling Interests | $7.5 | $11.9 | | **Total Stockholders' Equity** | **$227.1** | **$66.9** | | **Total Liabilities and Stockholders' Equity** | **$309.6** | **$100.2** | [Consolidated Statements of Operations and Comprehensive Income (Loss)](index=72&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income%20(Loss)) DocGo achieved $318.7 million in net revenue in 2021, a substantial increase from $94.1 million in 2020, transitioning from a $14.8 million net loss in 2020 to a $19.2 million net income in 2021 Consolidated Statements of Operations and Comprehensive Income (Loss) (USD) | Indicator | 2021 | 2020 | | :--- | :--- | :--- | | Net Revenue | $318,718,580 | $94,090,658 | | Cost of Revenue | $208,971,062 | $62,743,607 | | Total Operating Expenses | $303,361,282 | $108,848,341 | | Operating Income/(Loss) | $15,357,298 | $(14,757,683) | | Total Other Income (Expense) | $4,437,887 | $125,914 | | Net Income/(Loss) Before Income Taxes | $19,795,185 | $(14,631,769) | | Income Tax Expense | $(615,697) | $(167,443) | | Net Income/(Loss) | $19,179,488 | $(14,799,212) | | Net Loss Attributable to Non-Controlling Interests | $(4,564,270) | $(439,268) | | Net Income/(Loss) Attributable to DocGo Inc. Stockholders | $23,743,758 | $(14,359,944) | | Other Comprehensive Income/(Loss) | $16,038 | $196,345 | | Total Comprehensive Income/(Loss) | $23,759,796 | $(14,163,599) | | Basic Net Income/(Loss) Per Share | $0.30 | $(0.25) | | Diluted Net Income/(Loss) Per Share | $0.25 | $(0.25) | - Total revenue for 2021 was **$318.7 million**, representing a **239% increase** from 2020[425](index=425&type=chunk) - The company achieved **net income of $19.18 million in 2021**, compared to a **net loss of $14.8 million in 2020**[425](index=425&type=chunk) [Consolidated Statements of Changes in Stockholders' Equity](index=73&type=section&id=Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) DocGo's stockholders' equity significantly increased in 2021, primarily due to net proceeds from common stock issuance related to the Motion merger, with total equity attributable to DocGo Inc. shareholders reaching $219.6 million Summary of Consolidated Statements of Changes in Stockholders' Equity (USD) | Indicator | 2021-12-31 | 2020-12-31 | | :--- | :--- | :--- | | Class A Common Stock | $10,013 | $0 | | Additional Paid-in Capital | $283,161,216 | $142,346,852 | | Accumulated Deficit | $(63,556,714) | $(87,300,472) | | Accumulated Other Comprehensive Loss | $(32,501) | $(48,539) | | Total Equity Attributable to DocGo Inc. Stockholders | $219,582,014 | $54,997,841 | | Non-Controlling Interests | $7,475,010 | $11,949,200 | | **Total Stockholders' Equity** | **$227,057,024** | **$66,947,041** | - In 2021, the company significantly increased stockholders' equity through a **net increase of $114.6 million in additional paid-in capital** from common stock issuance related to the Motion merger[428](index=428&type=chunk) - As of December 31, 2021, the accumulated deficit decreased from **$87.3 million in 2020 to $63.56 million**, reflecting profitability in 2021[428](index=428&type=chunk) [Consolidated Statements of Cash Flows](index=74&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In 2021, DocGo used $1.9 million in operating cash and $8.6 million in investing cash, while financing activities provided $155.2 million, primarily from the Motion merger, resulting in a $144.6 million net increase in cash and restricted cash Consolidated Statements of Cash Flows (USD) | Cash Flow Category | 2021 | 2020 | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | $(1,947,420) | $(10,654,692) | | Net Cash Flow from Investing Activities | $(8,589,185) | $(6,040,022) | | Net Cash Flow from Financing Activities | $155,206,476 | $(812,093) | | Effect of Exchange Rate Changes | $(21,414) | $196,345 | | Net Increase/(Decrease) in Cash and Restricted Cash | $144,648,457 | $(17,310,462) | | Cash and Restricted Cash at Beginning of Period | $34,457,273 | $51,767,735 | | Cash and Restricted Cash at End of Period | $179,105,730 | $34,457,273 | - Operating activities used **$1.9 million in cash in 2021**, primarily due to a **$57.99 million increase in accounts receivable**, partially offset by a **$32.6 million increase in accounts payable and accrued liabilities**[431](index=431&type=chunk)[378](index=378&type=chunk) - Investing activities used **$8.59 million in cash in 2021**, primarily for the acquisition of property and equipment (**$4.81 million**) and business and intangible assets (**$3.15 million**)[431](index=431&type=chunk)[380](index=380&type=chunk) - Financing activities provided **$155.2 million in cash in 2021**, primarily from **$178.1 million in net proceeds** from common stock issuance related to the Motion merger, partially offset by **$2.2 million in finance lease obligation payments** and **$19.96 million in merger issuance costs**[431](index=431&type=chunk)[382](index=382&type=chunk) [Notes to Consolidated Financial Statements](index=76&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) This section provides detailed notes to the consolidated financial statements, covering company organization, significant accounting policies, balance sheet items, business segments, equity, stock-based compensation, leases, and subsequent events - The notes detail the organization and business operations of DocGo Inc. and its subsidiaries, including its role as a medical transportation and mobile health services company, and the merger with Motion Acquisition Corp[438](index=438&type=chunk)[439](index=439&type=chunk)[441](index=441&type=chunk) - Note 2 summarizes significant accounting policies, including principles of consolidation (for the variable interest entity MD1), foreign currency translation, use of estimates, concentrations

[Explanatory Note](index=3&type=section&id=Explanatory%20Note) This report details Motion Acquisition Corp.'s financial position and operations prior to its business combination with Ambulnz, Inc. [Business Combination](index=3&type=section&id=Business%20Combination) This report reflects Motion Acquisition Corp.'s status before its November 5, 2021 merger with Ambulnz, Inc., which resulted in the formation of DocGo Inc. - Motion Acquisition Corp. completed its business combination with Ambulnz, Inc. on **November 5, 2021**, after the reporting period[6](index=6&type=chunk) - Upon closing the business combination, the company changed its name from Motion Acquisition Corp. to **DocGo Inc.**[7](index=7&type=chunk) - This report primarily presents information regarding Motion Acquisition Corp. prior to the business combination's closing[8](index=8&type=chunk)[9](index=9&type=chunk) [PART I. FINANCIAL INFORMATION](index=5&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the company's unaudited condensed financial statements, management's analysis, market risk disclosures, and internal controls. [Condensed Financial Statements](index=5&type=section&id=Item%201.%20Condensed%20Financial%20Statements) These statements present the company's financial position as a blank check company, highlighting $115 million in trust assets and a $0.5 million net loss for the nine months ended September 30, 2021. [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet shows total assets of **$115.3 million** as of September 30, 2021, primarily from the Trust Account, with a stockholders' deficit of **$12.7 million**. Condensed Consolidated Balance Sheet Data (Unaudited) | Balance Sheet Items | Sep 30, 2021 ($) | Dec 31, 2020 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash | $59,319 | $878,653 | | Investments held in Trust Account | $115,000,482 | $115,020,078 | | **Total Assets** | **$115,288,058** | **$116,067,608** | | **Liabilities** | | | | Warrant liabilities | $8,595,000 | $9,040,670 | | Deferred underwriting commissions | $4,025,000 | $4,025,000 | | **Total Liabilities** | **$12,954,182** | **$13,225,520** | | **Class A common stock subject to possible redemption** | $115,000,000 | $115,000,000 | | **Total Stockholders' Deficit** | **($12,666,124)** | **($12,157,912)** | [Unaudited Condensed Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended September 30, 2021, the company reported **net income of $0.54 million**, primarily from warrant fair value changes, resulting in a **net loss of $0.51 million** for the nine-month period. Statement of Operations Highlights (Unaudited) | Metric | Three Months Ended Sep 30, 2021 ($) | Nine Months Ended Sep 30, 2021 ($) | | :--- | :--- | :--- | | General and administrative expenses | $348,325 | $976,486 | | Loss from operations | ($348,325) | ($976,486) | | Change in fair value of warrant liabilities | $891,332 | $445,670 | | **Net income (loss)** | **$544,487** | **($508,212)** | | Basic and diluted net income (loss) per Class A common share | $0.04 | ($0.04) | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) These notes detail the post-period business combination, accounting policies including redeemable stock reclassification, IPO specifics, and warrant terms. - The business combination with Ambulnz, Inc. was completed on **November 5, 2021**, after the reporting period[26](index=26&type=chunk)[105](index=105&type=chunk) - Financial statements were revised to classify redeemable Class A common stock as **temporary equity** per ASC 480, reclassifying amounts from stockholders' equity for prior periods[42](index=42&type=chunk)[43](index=43&type=chunk) - The Initial Public Offering on **October 19, 2020**, generated **$115.0 million** in gross proceeds from 11,500,000 units at $10.00 per unit[71](index=71&type=chunk) - As of September 30, 2021, derivative warrant liabilities totaled **$8.6 million**, with **$4.0 million** in deferred underwriting commissions payable upon business combination[83](index=83&type=chunk)[101](index=101&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This MD&A covers the company's pre-merger operations, reporting a **$0.5 million net loss** for the nine months ended September 30, 2021, and discusses critical accounting policies. - The company, a blank check entity, merged with Ambulnz, Inc. (DocGo) on **November 5, 2021**, following an agreement on March 8, 2021[109](index=109&type=chunk)[110](index=110&type=chunk) - For the nine months ended September 30, 2021, the company reported a **net loss of approximately $0.5 million**, primarily due to **$1.0 million** in general and administrative expenses, partially offset by a **$0.4 million** positive change in warrant fair value[119](index=119&type=chunk) - As of September 30, 2021, the company held approximately **$60,000 in cash** and had a **negative working capital of approximately $47,000**[113](index=113&type=chunk) - Critical accounting policies encompass derivative warrant liabilities and the classification of redeemable Class A common stock as **temporary equity**[123](index=123&type=chunk)[124](index=124&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=27&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is exempt from providing quantitative and qualitative disclosures about market risk. - The company is exempt from providing this information as a **smaller reporting company** under Rule 12b-2 of the Exchange Act[130](index=130&type=chunk) [Controls and Procedures](index=27&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2021, with no material changes to internal control over financial reporting. - Management determined that disclosure controls and procedures were **effective** as of September 30, 2021[131](index=131&type=chunk) - No material changes occurred in the company's internal control over financial reporting during the third quarter of 2021[133](index=133&type=chunk) [PART II. OTHER INFORMATION](index=28&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section details unregistered equity sales, use of proceeds, and a list of exhibits filed with the report. [Unregistered Sales of Equity Securities and Use of Proceeds](index=28&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section outlines the **$115 million** gross proceeds from the IPO and **$3.8 million** from a private placement of warrants, with **$115 million** deposited into the Trust Account. - The Initial Public Offering generated **$115 million** in gross proceeds from 11,500,000 units at $10.00 per unit[135](index=135&type=chunk) - A private placement of 2,533,333 warrants at $1.50 each generated **$3.8 million** in total proceeds[136](index=136&type=chunk) - A total of **$115,000,000** from the IPO and private placement was deposited into the Trust Account[138](index=138&type=chunk) [Exhibits](index=28&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including officer certifications and Inline XBRL documents. - Certifications from the Chief Executive Officer and Chief Financial Officer are included as required by the **Sarbanes-Oxley Act of 2002**[141](index=141&type=chunk) - Inline XBRL documents are provided as exhibits for financial data tagging[141](index=141&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to________________ MOTION ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) | --- | --- | --- | |------------------------------------|----------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to________________ MOTION ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) | --- | --- | --- | |------------------------------------|---------------- ...

PART I [Business](index=5&type=section&id=Item%201.%20Business) Motion Acquisition Corp. is a blank check company with no operations, focused on a business combination, having entered a merger agreement with DocGo - The company is a blank check or 'shell company' whose primary purpose is to effect a business combination[18](index=18&type=chunk) Initial Public Offering and Private Placement Details | Offering/Placement | Date | Securities | Price per Security | Gross Proceeds | | :--- | :--- | :--- | :--- | :--- | | Initial Public Offering | Oct 19, 2020 | 11,500,000 Units | $10.00 | $115,000,000 | | Private Placement | Oct 19, 2020 | 2,533,333 Warrants | $1.50 | $3,800,000 | - On March 8, 2021, the company entered a definitive merger agreement with Ambulnz, Inc. (dba DocGo), involving the exchange of **83,600,000 shares** of Class A common stock[25](index=25&type=chunk)[27](index=27&type=chunk) - The company faces significant competition from other blank check companies, private equity groups, and operating businesses for strategic acquisitions, a trend increasing since late 2020[57](index=57&type=chunk)[58](index=58&type=chunk) [Risk Factors](index=14&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks as a blank check company, including the deadline for business combination, competition, conflicts of interest, and potential liquidation - The company must complete its initial business combination by **October 19, 2022**, or face liquidation and worthless warrants[109](index=109&type=chunk)[152](index=152&type=chunk) - A significant conflict of interest exists as the Sponsor, officers, and directors will lose their entire investment if a business combination is not completed[202](index=202&type=chunk)[203](index=203&type=chunk) - The search for a business combination may be adversely affected by the COVID-19 pandemic, impacting travel, meetings, and financing capabilities[142](index=142&type=chunk)[143](index=143&type=chunk)[144](index=144&type=chunk) - The company's securities may be delisted from Nasdaq for failing to meet listing requirements, limiting liquidity and potentially subjecting them to 'penny stock' rules[215](index=215&type=chunk)[216](index=216&type=chunk) - As an 'emerging growth company,' reduced disclosure obligations may make its securities less attractive and performance harder to compare[254](index=254&type=chunk)[255](index=255&type=chunk) [Unresolved Staff Comments](index=43&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments - Not applicable[278](index=278&type=chunk) [Properties](index=43&type=section&id=Item%202.%20Properties) The company's executive offices are located in New York, NY, with space provided at no charge by its counsel - The company's executive offices are located at 405 Lexington Avenue, New York, NY, with space provided at no charge by Graubard Miller[279](index=279&type=chunk) [Legal Proceedings](index=43&type=section&id=Item%203.%20Legal%20Proceedings) The company reports no legal proceedings - None[280](index=280&type=chunk) [Mine Safety Disclosures](index=43&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This section is not applicable to the company - Not applicable[281](index=281&type=chunk) PART II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=44&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's Class A common stock, warrants, and units are listed on Nasdaq, with **$115 million** from its IPO held in trust for a business combination - The company's securities trade on Nasdaq under symbols MOTNU (Units), MOTN (Class A common stock), and MOTNW (Public Warrants)[284](index=284&type=chunk) - The company has not paid cash dividends and does not plan to before completing a business combination, with future payments dependent on the post-combination entity's financial condition[286](index=286&type=chunk) - Following the IPO and Private Placement, **$115 million** was placed in the Trust Account, with other funds used for target business identification[292](index=292&type=chunk)[294](index=294&type=chunk) [Selected Financial Data](index=45&type=section&id=Item%206.%20Selected%20Financial%20Data) This section is not applicable to the company - Not applicable[296](index=296&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=46&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) As a blank check company, operations are limited to formation and business combination search, resulting in a **$148,751** net loss for 2020, with **$879,000** in cash for liquidity - On March 8, 2021, the company entered a merger agreement with DocGo and concurrently secured **$125 million** in gross proceeds through a PIPE financing agreement[301](index=301&type=chunk)[307](index=307&type=chunk) - As of December 31, 2020, the company had an unrestricted cash balance of approximately **$879,000** and working capital of approximately **$888,000**[310](index=310&type=chunk) Results of Operations (Inception to Dec 31, 2020) | Metric | Amount (USD) | | :--- | :--- | | Net Loss | ($148,751) | | Operating and formation costs | $168,830 | | Interest earned on Trust Account | $20,078 | - Critical accounting policies include classifying redeemable Class A common stock outside of permanent equity and using the two-class method for net income (loss) per share calculation[318](index=318&type=chunk)[319](index=319&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=48&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section is not applicable to the company - Not applicable[321](index=321&type=chunk) [Financial Statements and Supplementary Data](index=49&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) Audited financial statements for 2020 show total assets of **$116.1 million**, liabilities of **$4.2 million**, a net loss of **$148,751**, and a subsequent merger agreement with DocGo Balance Sheet Summary as of December 31, 2020 | Category | Amount (USD) | | :--- | :--- | | **Assets** | | | Cash and marketable securities in Trust Account | 115,020,078 | | Total Assets | 116,067,608 | | **Liabilities & Equity** | | | Total Liabilities | 4,184,850 | | Class A common stock subject to redemption | 106,882,750 | | Total Stockholders' Equity | 5,000,008 | Statement of Operations (Inception to Dec 31, 2020) | Metric | Amount (USD) | | :--- | :--- | | Loss from operations | (168,830) | | Interest earned on Trust Account | 20,078 | | **Net Loss** | **(148,751)** | - Subsequent to year-end, on March 8, 2021, the company entered a definitive merger agreement with Ambulnz, Inc. (dba DocGo), expected to close in Q2 2021[349](index=349&type=chunk)[412](index=412&type=chunk) [Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](index=67&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20With%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants on accounting and financial disclosure - None[429](index=429&type=chunk) [Controls and Procedures](index=67&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective as of December 31, 2020, with no material changes to internal controls reported - The CEO and CFO concluded the company's disclosure controls and procedures were effective as of December 31, 2020[432](index=432&type=chunk) - No report on internal control over financial reporting is included due to the transition period for newly public companies[433](index=433&type=chunk) [Other Information](index=67&type=section&id=Item%209B.%20Other%20Information) This section is not applicable - Not applicable[435](index=435&type=chunk) PART III [Directors, Executive Officers and Corporate Governance](index=68&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) The company is led by an experienced executive team and a board with three independent committees, operating under an adopted Code of Ethics - The executive team includes James M. Travers (Chairman), Michael Burdiek (CEO), Richard Vitelle (CFO), and Garo Sarkissian (EVP, Corporate Development)[438](index=438&type=chunk) - The board has three standing committees (Audit, Compensation, Nominating), each composed entirely of independent directors Andrew G. Flett, Mark Licht, and Kyle Messman[449](index=449&type=chunk)[451](index=451&type=chunk)[456](index=456&type=chunk)[463](index=463&type=chunk) - The company has adopted a Code of Ethics for its directors, officers, and employees[468](index=468&type=chunk) [Executive Compensation](index=73&type=section&id=Item%2011.%20Executive%20Compensation) No cash compensation has been paid to officers or directors for services, with only expense reimbursement prior to a business combination - No cash compensation has been paid to officers or directors for services, with only reimbursement for out-of-pocket expenses prior to a business combination[469](index=469&type=chunk) - Compensation for management remaining after the business combination will be determined by the post-combination board of directors[470](index=470&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=73&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) As of March 29, 2021, Motion Acquisition LLC (Sponsor) and officers/directors beneficially owned **20.0%** of common stock, with Adage Capital Partners holding **7.0%** Beneficial Ownership as of March 29, 2021 | Beneficial Owner | Number of Shares | Percentage of Outstanding | | :--- | :--- | :--- | | Motion Acquisition LLC (Sponsor) | 2,875,000 | 20.0% | | All officers and directors as a group | 2,875,000 | 20.0% | | Adage Capital Partners, L.P. | 1,000,000 | 7.0% | [Certain Relationships and Related Transactions, and Director Independence](index=75&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) The company engaged in related party transactions with its Sponsor, including the sale of Founder Shares and Private Placement Warrants, and has three independent directors - The Sponsor, Motion Acquisition LLC, purchased **2,875,000 Founder Shares** for a capital contribution of **$25,000**[478](index=478&type=chunk) - The Sponsor purchased **2,533,333 Private Placement Warrants** at **$1.50 per warrant** for an aggregate of **$3.8 million**[479](index=479&type=chunk) - The board has determined that Andrew Flett, Mark Licht, and Kyle Messman are independent directors per Nasdaq listing standards[491](index=491&type=chunk) [Principal Accountant Fees and Services](index=77&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) The company's independent auditor is WithumSmith+Brown, PC, with total audit fees of approximately **$68,900** for the period ending December 31, 2020 Accountant Fees (Fiscal 2020) | Fee Category | Amount (USD) | | :--- | :--- | | Audit Fees | ~$68,900 | | Audit-Related Fees | $0 | | Tax Fees | $0 | | All Other Fees | $0 | PART IV [Exhibits, Financial Statement Schedules](index=78&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists all exhibits filed with the Form 10-K, including the Merger Agreement with Ambulnz Inc. and other key corporate documents - This section provides an index of all exhibits filed with the Form 10-K, including financial statements and various material agreements[499](index=499&type=chunk)[500](index=500&type=chunk) [Form 10-K Summary](index=79&type=section&id=Item%2016.%20Form%2010-K%20Summary) This section is not applicable - None[502](index=502&type=chunk)